Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers

• DOI: 10.1038/s41408-025-01257-1
• Publication Date: 2025-03-26T19:57:38Z
• Authors: Timothy J. Voorhees; Eric M. McLaughlin; Pallawi Torka; Jorge Florindez; Na Hyun Kim; Tamara K. Moyo; Heather Reves; Nuttavut Sumransub; Saarang Deshpande; Ashley Rose; Cassandra Duarte; Muhammad Salman F...; Showkat Hamid; Suki Subbiah; Sabarish Ayyappan; Lauren Shea; Matt Cortese; Krish Patel; Ajay Major; Hayder Saeed; Jakub Svoboda; Sanjal Desai; Praveen Ramakrish...; Mehdi Hamadani; Natalie Grover; Narendranath Epperla